Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Restifo, Nicholas P., Haworth, Leah R., Levy, Catherine, Mavroukakis, Sharon A., Nichol, Geoff, Yellin, Michael J., Rosenberg, Steven A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.06.205

Cited by (1,000)

Items 401–500 of 1,000

The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma
Lee D. Cranmer, Evan M. Hersh · 2007 · Cancer Investigation
Current management and novel agents for malignant melanoma
Byung Lee, Nikhil Mukhi, Delong Liu · 2012 · Journal of Hematology & Oncology
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response
Minghao Wu, Yanyan Zhang, Yuwei Zhang, Ying Liu, Mingjie Wu, Zhaoxiang Ye · 2019 · Radiology Imaging Cancer
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
Melissa L. Bastacky, Hong Wang, Dylan D. Fortman, Zahra Rahman, Gerard P. Mascara, Timothy Brenner, Yana George Najjar, Jason J. Luke, John M. Kirkwood, Hassane M. Zarour et al. · 2021 · Frontiers in Oncology
Recent advances and hurdles in melanoma immunotherapy
Camilla Jandus, Daniel E. Speiser, Pedro J. Romero · 2009 · Pigment Cell & Melanoma Research
CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease
S. Fevery, An Billiau, Ben Sprangers, Omer Rutgeerts, Caroline Lenaerts, Jozef Goebels, Willy Landuyt, Ahmad Kasran, Louis Boon, Xavier Sagaert et al. · 2007 · Leukemia
Nivolumab-induced thyroid dysfunction
Ryota Tanaka, Yasuhiro Fujisawa, Hiroshi Maruyama, Yasuhiro Nakamura, Koji Yoshino, Mikio Ohtsuka, Manabu Fujimoto · 2016 · Japanese Journal of Clinical Oncology
Immunotherapy and the concept of a clinical cure
Alexander M.M. Eggermont, Guido Kroemer, Laurence Zitvogel · 2013 · European Journal of Cancer
Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans
Jason Boer, Ruth Young-Sciame, F. Lee, Kevin J Bowman, Xiaoqing Yang, Junya Shi, Frank M. Nedza, William E. Frietze, Laurine G. Galya, Andrew P. Combs et al. · 2016 · Drug Metabolism and Disposition
Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
Michelle Coureau, Anne‐Pascale Meert, Thierry Berghmans, Bogdan Dragoş Grigoriu · 2020 · Frontiers in Medicine
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
Chih‐Hung Lee, Takashi Kakinuma, Julia Wang, Hong Zhang, Douglas C. Palmer, Nicholas P. Restifo, Samuel T. Hwang · 2006 · Molecular Cancer Therapeutics
Novel antibodies targeting immune regulatory checkpoints for cancer therapy
Chern Siang Lee, Mark Steven Cragg, Martin J. Glennie, Peter Johnson · 2013 · British Journal of Clinical Pharmacology
Towards progress on DNA vaccines for cancer
Devin B. Lowe, Michael H. Shearer, Cynthia Jumper, Ronald C. Kennedy · 2007 · Cellular and Molecular Life Sciences
Immunotherapy for advanced melanoma: Fulfilling the promise
Helen J Gogas, Aristidis Polyzos, John M. Kirkwood · 2013 · Cancer Treatment Reviews
Translatability scoring in drug development: eight case studies
Alexandra Wendler, Martin Wehling · 2012 · Journal of Translational Medicine
Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion
Kevin H. Toomer, Zhibin Chen · 2014 · Frontiers in Immunology
The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases
Karolina Wojciechowicz, Marta Spodzieja, Katarzyna Aleksandra Lisowska, Anna Wardowska · 2022 · Cellular Immunology
Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature
Al-Ola A. Abdallah, Aline Herlopian, Rahul Ravilla, Meghana Bansal, Sowmya Chandra-Reddy, Fade Aziz Mahmoud, Shirley Ong, Murat Gökden, Laura Fulper Hutchins · 2015 · Journal of Oncology Pharmacy Practice
Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia Maria Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, Gerald Steven Falchook et al. · 2017 · Molecular Cancer Therapeutics
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A. Ascierto, John B.A.G. Haanen, Enrique Espinosa, Лев Вадимович Демидов, Claus Garbe, Michele Guida, Paul C. Lorigan, Vanna Chiarion‐Sileni, Helen J Gogas et al. · 2019 · European Journal of Cancer
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
Pierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, Rocco Giannicola, Rita Maria Agostino, Nicoletta Staropoli, Alessandra Strangio, Teresa Del Giudice, Valerio Nardone, Maria Altomonte et al. · 2020 · Journal for ImmunoTherapy of Cancer
Costimulation blockade: towards clinical application
Timothy, A. Weaver · 2007 · Frontiers in bioscience
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Xiang‐Yang Wang, Daming Zuo, Devanand Sarkar, Paul B. Fisher · 2011 · Expert Opinion on Pharmacotherapy
Profile of ipilimumab and its role in the treatment of metastatic melanoma
Scott Eric Woodman, Patel · 2011 · Drug Design Development and Therapy
Anti–CTLA-4 Antibody Adjuvant Therapy in Melanoma
Alexander M.M. Eggermont, Alessandro Testori, Michele Maio, Caroline Robert · 2010 · Seminars in Oncology
Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer
Julie Nicole Graff, Sachin Puri, Carlo Bruno Bifulco, Bernard A. Fox, Tomasz M. Beer · 2014 · Cancer Immunology Research
Ipilimumab-Associated Retinopathy
Jonathan D. Crews, Aniruddha Kishandutt Agarwal, Loren S. Jack, Ding Xu, V. Diana, Quan Dong Nguyen · 2015 · Ophthalmic surgery, lasers & imaging retina
Systematic review with meta‐analysis: effectiveness of anti‐inflammatory therapy in immune checkpoint inhibitor‐induced enterocolitis
Hajir Ibraheim, Samantha Baillie, Mark Samaan, Hamzah Abu‐Sbeih, Yinghong Wang, Nicholas Joseph Talley, Michael P. Jones, Nick Powell · 2020 · Alimentary Pharmacology & Therapeutics
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Christophe Maritaz, Sophie Broutin, Nathalie Chaput, Aurélien Marabelle, Angélo Paci · 2022 · Journal of Hematology & Oncology
Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens
Anik L. Côté, Peisheng Zhang, Jeremy A. O’Sullivan, Valerie L. Jacobs, Carli R. Clemis, Shimon Sakaguchi, Jose Alejandro Guevara-Patino, Mary Jo Turk · 2010 · The Journal of Immunology
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management
Yuwen Zhou, Yan Wang, Ruo-Lan Xia, Jiyan Liu, Xuelei Ma · 2022 · International Journal of Ophthalmology
Ipilimumab (Yervoy) and the TGN1412 catastrophe
Tibor Bakács, Jitendra N. Mehrishi, Ralph W. Moss · 2011 · Immunobiology
Prostate cancer vaccines
Sean M. Geary, Aliasger K. Salem · 2013 · OncoImmunology
Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
Marina Tsoli, Gregory Kaltsas, Anna G. Angelousi, Krystallenia Alexandraki, Harpal Singh Randeva, Eva N. Kassi · 2020 · Cancer Management and Research
Therapeutic Vaccines for Prostate Cancer
Christopher P. Tarassoff, Philip Martin Arlen, James L. Gulley · 2006 · The Oncologist
The importance of co‐stimulation in the orchestration of T helper cell differentiation
Jonathan M. Coquet, Lisa Rausch, Jannie G. Borst · 2015 · Immunology and Cell Biology
Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
Sanjiv S. Agarwala · 2010 · Melanoma Research
Retinal toxicities of Systemic Anticancer Drugs.
Supriya Arora, Thamolwan Surakiatchanukul, T. Arora, M. Errera, Hitesh Agrawal, M. Lupidi, J. Chhablani · 2021 · Survey of ophthalmology
PET/CT, MR, and PET/MR in Lymphoma and Melanoma
Nina F. Schwenzer, Anna Christina Pfannenberg · 2015 · Seminars in Nuclear Medicine
Pathological Characterization of Nivolumab-Related Liver Injury in a Patient with Glioblastoma
Matteo Simonelli, Luca Di Tommaso, Marina Baretti, Armando Santoro · 2016 · Immunotherapy
Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors
Nicole A. Romanski, Rikke Boedker Holmstroem, Eva Ellebæk, Inge Marie Svane · 2020 · European Journal of Cancer
Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update
Katharina Charlotte Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Kai‐Martin Thoms, Selma Ugurel, Lisa Zimmer, Ralf Gutzmer · 2020 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
Engineered in vitro tumor models for cell-based immunotherapy
Yuta Ando, Chelsea F. Mariano, Keyue Shen · 2021 · Acta Biomaterialia
Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology
Michele W.L. Teng, David S. Ritchie, Paul Joseph Neeson, Mark John Smyth · 2010 · Current topics in microbiology and immunology
Novel treatment strategies for malignant melanoma: A new beginning?
Bernd Kasper, Véronique D’Hondt, Pierre Vereecken, Ahmad Hussein Awada · 2007 · Critical Reviews in Oncology/Hematology
Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches
Alexander Batista-Duharte, Fakhri Hassouneh, Pablo Álvarez-Heredia, Alejandra Pera, Rafael Solana · 2022 · Pharmaceutics
Late-Onset Paraplegia after Complete Response to Two Cycles of Ipilimumab for Metastatic Melanoma
Grainne Mary O'Kane, Tomás G. Lyons, Gabrielle Colleran, Marzuki Wan Ahmad, Scheryll Paula Alken, Eoin Carl Kavanagh, David A. Fitzpatrick, Brian Murray, Catherine Margaret Kelly · 2014 · Oncology Research and Treatment
Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells
Karen C. Galvin, Lydia Dyck, Neil A. Marshall, Anna M. Stefanska, Kevin P. Walsh, Barry Moran, Sarah C. Higgins, Lara S. Dungan, Kingston H. G. Mills · 2013 · Cancer Immunology Immunotherapy
Penile primary melanoma: analysis of 6 patients treated at Brazilian national cancer institute in the last eight years
Gustavo Ruschi Bechara, Aline Barros de Santos Schwindt, Antônio Augusto Ornellas, Diogo Eugenio Abreu da Silva, Felipe Lott, Franz Santos de Campos · 2013 · International braz j urol
Predictive factors for immunotherapy in melanoma.
Cristina Teixidó, María González‐Cao, Niki Karachaliou, Rafael Rosell · 2015 · Europe PMC (PubMed Central)
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma
Alejo Rodríguez‐Vida, Michiel Hendrik Strijbos, Thomas E. Hutson · 2016 · ESMO Open
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Wouter Ouwerkerk, Mirjam van den Berg, Sanne van der Niet, Jacqueline Limpens, Rosalie M. Luiten · 2019 · Melanoma Research
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation
Ion G. Motofei · 2021 · Seminars in Cancer Biology
Ipilimumab in melanoma
Pol M. Specenier · 2016 · Expert Review of Anticancer Therapy
Overcoming immunological tolerance to melanoma: targeting CTLA-4
HODI, F Stephen · 2010 · Asia-Pacific Journal of Clinical Oncology
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Sanjiv S. Agarwala, Antoni Ribas · 2010 · Journal of Immunotherapy
Management of Immune Checkpoint Inhibitor Toxicities
Quentin Durrechou, Charlotte Domblides, Baptiste Sionneau, Félix Lefort, Amandine Quivy, Alain Ravaud, Marine Gross‐Goupil, Amaury Daste · 2020 · Cancer Management and Research
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.
Jingjing Sun, Jade S. Schiffman, Anitha Raghunath, Derek Ng Tang, Hong Chen, Padmanee Sharma · 2008 · PubMed Central
Cancer vaccines as a therapeutic modality: the long trek
Angus George Dalgleish, Mike Whelan · 2006 · Cancer Immunology Immunotherapy
The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides
Rebecca Claire Harris, Kimberly A. Chianese‐Bullock, Gina R. Petroni, Jochen T. Schaefer, Louis B. Brill, Kerrington R. Molhoek, Donna H. Deacon, James W. Patterson, Craig Lee Slingluff · 2011 · Journal of Immunotherapy
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
James Leslie Alexander, Hajir Ibraheim, Bhavisha Sheth, Jessica Little, Muhammad Khan, Camellia Richards, Nikki Hunter, Dharmisha Chauhan, Raguprakash Ratnakumaran, Kathleen Mchugh et al. · 2021 · Journal for ImmunoTherapy of Cancer
Balance and Imbalance in the Immune System: Life on the Edge
Suzanne Louise Topalian, Arlene H. Sharpe · 2014 · Immunity
Targets of Protective Tumor Immunity
Glenn Dranoff · 2009 · Annals of the New York Academy of Sciences
Adverse Consequences of Immunostimulation
Rafael A. Ponce · 2008 · Journal of Immunotoxicology
Checkpoint blockade in combination with cancer vaccines
Michael Andrew Morse, Herbert Kim Lyerly · 2015 · Vaccine
Ipilimumab: a promising immunotherapy for melanoma.
Jaykumar Ranchodbhai Thumar, Harriet M. Kluger · 2010 · PubMed
A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy
Lisa A. Kottschade, Adam K. Brys, Tobias Peikert, Mabel M. Ryder, Laura E. Raffals, Jerry D. Brewer, Paul J. Mosca, Svetomir N. Markovic · 2016 · Melanoma Research
Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells
Margherita Passariello, Simona Camorani, Cinzia Vetrei, Stefania Ricci, Laura Cerchia, Claudia De Lorenzo · 2020 · Cancers
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
Steve Boudewijns, Harm Westdorp, Rutger H.T. Koornstra, Erik H.J.G. Aarntzen, Gerty Schreibelt, Jeroen H. A. Creemers, Cornelis J.A. Punt, Carl Gustav Figdor, I. Jolanda M. de Vries, Winald R. Gerritsen et al. · 2016 · Journal of Immunotherapy
Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
Sunita M C De Sousa, Nisa Sheriff, Chau H. Tran, Alexander Maxwell Menzies, Venessa Tsang, Georgina Venetia Long, Katherine Thuy Trang Tonks · 2018 · Pituitary
Tumor Vaccines for Breast Cancer
Karen S. Anderson · 2009 · Cancer Investigation
Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors
Ondřej Fiala, Ondřej Šorejs, Jan Šustr, Radek Kučera, Ondřej Topolčan, Jindřich Fínek · 2020 · Anticancer Research
Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
Luis H. Camacho · 2008 · Expert Opinion on Investigational Drugs
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
Ulrich Keilholz · 2008 · Journal of Immunotherapy
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
Cristina Maccalli, Diana Giannarelli, Filippo Capocefalo, Lorenzo Pilla, Ester Fonsatti, Anna Maria Di Giacomo, Giorgio Parmiani, Michele Maio · 2015 · OncoImmunology
Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
Anam A. Mazharuddin, Andrew T. Whyte, Dan S. Gombos, Nimisha Patel, Azadeh Razmandi, Amina Lateef Chaudhry, Nagham S Al-Zubidi · 2022 · Journal of Immunotherapy and Precision Oncology
Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort
Cyril Maire, Sophie Vercambre-Darras, Patrick Devos, M. D’Herbomez, Sylvain Dubucquoi, Laurent Mortier · 2011 · Journal of the European Academy of Dermatology and Venereology
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
Karl S. Peggs, Sergio A. Quezada · 2010 · Expert Review of Anticancer Therapy
Dendritic Cell-Based Tumor Vaccines and Antigen Presentation Attenuators
Kevin Evel-Kabler, Si‐Yi Chen · 2006 · Molecular Therapy
New approaches in metastatic melanoma: biological and molecular targeted therapies
Ferdy J. Lejeune, Donata Rimoldi, Daniel E. Speiser · 2007 · Expert Review of Anticancer Therapy
Strategies to Overcome Obstacles to Successful Immunotherapy of Melanoma
Franco Pandolfi, Rossella Cianci, Serena Lolli, Ian S. Dunn, E.E. Newton, Timothy J. Haggerty, L.A. Boyle, James T. Kurnick · 2008 · International Journal of Immunopathology and Pharmacology
Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction
Jordan J Wright, Douglas Buckner Johnson · 2022 · The Journal of Clinical Endocrinology & Metabolism
Melanoma vaccines: developments over the past 10 years
Oliver Klein, Christopher Schmidt, Ashley J. Knights, Ian D. Davis, Weisan Chen, Jonathan Simon Cebon · 2011 · Expert Review of Vaccines
Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Tímea Balatoni, Andrea Ladányi, Georgina Fröhlich, Kata Czirbesz, Peter Louis Kovacs, Gitta Pánczél, Eszter Bence, Vanda Plótár, Gabriella Liszkay · 2018 · Pathology & Oncology Research
Learning the drug target‐likeness of a protein
Huan Xu, HangYang Xu, Mingzhi Lin, Wei Wang, Zimu Li, JiaJu Huang, Yu Chen, Xin Chen · 2007 · PROTEOMICS
Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity
Taylor Sittler, Jun Min Zhou, Joosang Park, Noah K. Yuen, Stefanie Sarantopoulos, Joseph A. Mollick, Ravi Salgia, Anita Giobbie‐Hurder, Glenn Dranoff, Frank Stephen Hodi · 2008 · Clinical Cancer Research
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review
Zhao, Zhe, Wang, Xinfeng, Bao, Xiu-qi, Ning, Jingwen, Shang, Meiyu, Zhang, Dan · 2021 · Cancer Immunology, Immunotherapy
The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
Julie Delyon, Michele Maio, Célèste Lebbé · 2015 · Seminars in Oncology
Ipilimumab in the treatment of melanoma
Van Anh Trinh, Wen‐Jen Hwu · 2012 · Expert Opinion on Biological Therapy
Cancer immunology – development of novel anti-cancer therapies
Sacha I. Rothschild, Daniela S. Thommen, Wolfgang Moersig, Philipp Müller, Alfred Zippelius · 2015 · Swiss Medical Weekly
Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches
Ion G. Motofei · 2019 · Current Treatment Options in Oncology
Immunotherapeutic peptide vaccination with leukemia-associated antigens
Sylvie Rusakiewicz, Jeffrey J. Molldrem · 2006 · Current Opinion in Immunology
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Mingyi Ju, Jiaojiao Zhang, Zhuoyuan Deng, Minjie Wei, Lianghua Ma, Ting Chen, Zhao Lin · 2024 · Journal for ImmunoTherapy of Cancer
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
Beth H Sherrill, Jianmin Wang, S. Kotapati, Kevin M. Chin · 2013 · British Journal of Cancer
Update on the role of ipilimumab in melanoma and first data on new combination therapies
Michele Maio, Anna Maria Di Giacomo, Caroline Robert, Alexander M.M. Eggermont · 2013 · Current Opinion in Oncology
GK-1 peptide reduces tumor growth, decreases metastatic burden, and increases survival in a murine breast cancer model
Diana Torres‐García, Armando Pérez‐Torres, Karen Manoutcharian, U. Orbe, Rodolfo Servín-Blanco, Gladis Fragoso, Edda Sciutto · 2017 · Vaccine
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
Lorenzo Pilla, Cristina Maccalli · 2018 · Biomedicines
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
James Randall Patrinely, Anna K. Dewan, Douglas Buckner Johnson · 2020 · BioDrugs
Modulation of CTLA-4 and GITR for Cancer Immunotherapy
Francesca Avogadri, Jianda D. Yuan, Arvin S. Yang, David Schaer, Jedd D. Wolchok · 2010 · Current topics in microbiology and immunology
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient
Katharina C. Kaehler, Friederike Egberts, Paul C. Lorigan, Axel Hauschild · 2009 · Melanoma Research